DOVER, Del., June 25, 2025 – In a significant development for the clinical-stage immuno-oncology firm, Portage Biotech Inc. (PRTG) has confirmed its continued presence on the Nasdaq Capital Market. The announcement, made today, follows formal notification received on June 24, 2025, from The Nasdaq Stock Market LLC, validating the company’s compliance with all applicable listing requirements.
About Portage Biotech
Portage Biotech is carving a niche in the immuno-oncology landscape, focusing its efforts on a pipeline of novel biologics. These innovative therapies are engineered to leverage the power of the immune system in the fight against cancer.
Forward-Looking Statements
This news release contains forward-looking statements that are subject to various risks and uncertainties. These statements encompass the company’s strategic plans, future objectives, and anticipated operational outcomes, characterized by terms such as “believe,” “expects,” “anticipates,” “intends,” “estimates,” “will,” “may,” “plans,” “potential,” or similar expressions. Readers should be aware that such forward-looking statements are subject to the risk of unforeseen circumstances, as detailed in the Company’s filings. Actual results may differ materially from those projected in these forward-looking statements. Portage Biotech undertakes no obligation to update or revise these statements, except as legally required.
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/3319.html
